Table 1.
Preoperative and postoperative patient characteristics.
| Variables | Total patients (n = 150) |
|---|---|
| Age (y) | 66.23 ± 6.96 |
| Preoperative PSA (ng/ml) | 13.45 ± 13.51 |
| Prostate volume (ml) | 32.63 ± 13.64 |
| EPE width (mm) | 9.41 ± 12.78 |
| EPE depth (mm) | 0.54 ± 1.164 |
| Diabetic mellitus, n (%) | 29 (19.3%) |
| Hypertension, n (%) | 70 (46.7%) |
| Body mass index (kg/m2) | 24.49 ± 2.49 |
| Pathological Gleason score, n (%) | |
| 7≤ | 106 (70.7%) |
| ≥8 | 44 (29.3%) |
| Percent tumor volume (%) (gm) | 22.4 ± 17.80 |
| Lymphovascular invasion, n (%) | 34 (22.7%) |
| No. of PSM, n (%) | |
| 0 | 76 (50.7) |
| 1 | 38 (25.3) |
| 2 | 20 (13.3) |
| ≥3 | 16 (10.7) |
| Margin Gleason grade, n(%) | |
| 3 | 28 (18.7%) |
| 4 or 5 | 46 (30.7%) |
| Length of PSM (mm) | 4.69 ± 8.89 |
| Biochemical recurrence, n (%) | 53 (35.3%) |
| Operation method, n (%) | |
| Open | 69 (46.0%) |
| Robot | 81 (54.0%) |
| Follow-up duration (mo) | 41.46 ± 6.49 |
PSM, positive surgical margin; PSA, prostate-specific antigen.